Press Releases

2010 | 2009 | 2008 | 2007 | 2006
Keyword Search
 
DateTitle
12/13/07Court Grants Depomed's Motion for Summary Judgment of Patent Infringement Against IVAX
12/12/07Depomed Appoints James A. Schoeneck to Board of Directors
12/03/07Depomed Names Michael Sweeney Vice President of Product Development
11/01/07Depomed Reports Third Quarter 2007 Financial Results
10/30/07Depomed to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
10/29/07Depomed and King Pharmaceuticals Terminate Promotion Agreement for GLUMETZA(TM)
10/18/07Depomed to Announce Third Quarter 2007 Financial Results on November 1, 2007
10/11/07Depomed Announces Retirement of Chief Financial Officer John F. Hamilton
09/25/07Depomed and Watson Expand ProQuin(R) XR Promotion Agreement to Include Ob/Gyn Field
09/19/07Depomed Completes Patient Enrollment in Phase 2 Trial for Gabapentin GR for the Treatment of Menopausal Hot Flashes
09/17/07Depomed Announces Reduction in Force
09/12/07Depomed to Present at the ThinkEquity Partners 5th Annual Growth Conference
09/05/07Depomed Announces Positive Results of Phase 2a Proof-of-Concept GERD Study
08/29/07Depomed to Present at Thomas Weisel Partners Annual Healthcare Conference
08/27/07Dr. John Fara Retires as Chairman, President and CEO of Depomed; Mr. Carl Pelzel Appointed President and CEO
08/07/07Depomed Reports Second Quarter 2007 Financial Results
08/01/07Depomed to Announce Second Quarter 2007 Financial Results on Tuesday, August 7
07/23/07Depomed Enters into Promotion Agreement with Watson for ProQuin(R) XR
07/10/07Depomed Announces Results of Phase 3 Clinical Trial for Gabapentin GR(TM) In Postherpetic Neuralgia
07/05/07Depomed Reacquires the Rights to ProQuin(R) XR
06/13/07Depomed Initiates Dosing of Patients in Phase 2 Trial For Gabapentin GR For the Treatment of Menopausal Hot Flashes
06/08/07Depomed to Present at the 6th Annual Needham & Company Biotechnology & Medical Technology Conference
05/21/07Depomed to Present at the Bank of America 2007 Healthcare Conference
05/08/07Depomed Reports First Quarter 2007 Financial Results
04/30/07Depomed to Present at the Rodman & Renshaw Acumen Biofin 4th Annual Global Healthcare Conference
04/24/07Depomed to Announce First Quarter 2007 Financial Results on Tuesday, May 8
04/23/07Depomed Completes $20 Million Registered Direct Offering
04/04/07Depomed to Present at the CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference
04/02/07Depomed Files Prior Approval Supplement for 1000 mg Strength Tablets of Glumetza
03/23/07Depomed Appoints David Zenoff to Board OF Directors
03/14/07Depomed Reports 2006 Year End Financial Results
03/12/07Depomed Files Investigational New Drug Application for Gabapentin GR for the Treatment of Postmenopausal Hot Flashes
03/08/07Depomed Completes Patient Enrollment in Phase 3 Clinical Trial of Gabapentin GR in Postherpetic Neuralgia
02/28/07Depomed to Announce Fourth Quarter and Year End 2006 Financial Results on Wednesday, March 14
02/27/07Depomed to Present at The Oppenheimer Pain Management Conference
02/12/07Depomed and Biovail Sign License Agreement for Acuform(TM) Drug Delivery Technology